Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03675178
Other study ID # Anerning particle
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date September 22, 2018
Est. completion date December 31, 2019

Study information

Verified date September 2018
Source China Academy of Chinese Medical Sciences
Contact Yanming Xie, BA
Phone 86-13911112416
Email ktzu2018@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety and whether it can reduction of antibiotic use in the treatment of community-acquired pneumonia in children with Anerning granules combined with ceftriaxone sodium.


Description:

To evaluate the efficacy, safety and whether it can reduction of antibiotic use in the treatment of community-acquired pneumonia in children with Anerning granules combined with ceftriaxone sodium.In this study, a randomized, double blind, parallel control of placebo, multi-center clinical study will be established. According to the relevant regulations of the CFDA, 216 cases need to be registered at least.The aim population is children who suffering of community-acquired pneumonia from September 2018 to December 2019. These cases will be devided into treatment group(Anerning particle+ Intravenous ceftriaxone sodium),control group(Anerning particle simulants+ Intravenous ceftriaxone sodium). Each group will be treated for 10 days hospitalization and if there is adverse drug reaction during treatment, follow-up until the laboratory indicators are normal. The efficacy indicators of this study were mainly from three dimensions: Frequency of antibiotics at the clinical endpoint, Total disease efficiency, Clinical recovery time. The symptom scores changes of each group before and after treatment were observed.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 216
Est. completion date December 31, 2019
Est. primary completion date June 30, 2019
Accepts healthy volunteers No
Gender All
Age group 1 Year to 5 Years
Eligibility Inclusion Criteria:

1. Meet the diagnostic criteria for children's CAP Western medicine and consider bacterial infection;

2. Those who meet the diagnostic criteria of TCM syndrome differentiation of wind-heat and closed lung syndrome;

3. Children aged 1 to 5 years old;

4. Within 48 hours of onset of CAP;

5. The informed consent process is in compliance with the regulations, and the legal representative signs the informed consent form.

Exclusion Criteria:

1. Chest X-ray films showed obvious lung tumors and tuberculosis;

2. Those with acute infectious diseases such as measles, whooping cough, and influenza;

3. Other upper respiratory tract infections, wheezing-like bronchitis, bronchial asthma, bronchial foreign bodies and other respiratory diseases;

4. Children with severe malnutrition and immunodeficiency;

5. Combine severe primary diseases such as severe heart, liver, kidney, digestion and hematopoietic system;

6. Those who meet the CAP (severe) Western diagnostic criteria for children;

7. Clinically diagnosed or clinically considered viral pneumonia, Mycoplasma pneumoniae pneumonia;

8. allergic constitution (allergic to more than 2 types of substances), or allergic to penicillins, cephalosporin antibiotics and Anering granules and their components;

9. Researchers believe that it is not appropriate to join the group.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Anerning particle
Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g,for 10 days.When the condition is cured, stop the medicine at any time.
control group
Anerning particle placebo ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g,for 10 days.When the condition is cured, stop the medicine at any time.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
China Academy of Chinese Medical Sciences The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Outcome

Type Measure Description Time frame Safety issue
Primary Whether Anerning particle can reduce the use of antibiotics Frequency of antibiotics (DDDs) at clinical endpoints of the two groups After 10 days of medication.When the condition is cured, stop the medicine at any time.
Secondary The chest X-ray of 216 participants will be assessed. If the chest radiograph returns to normal, it indicates that the patient has recovered. The maximum time for administration according to the protocol is 10 days, and the drug can be stopped at any time during clinical cure. If it is not good to change on the 6th day of treatment, use other measures.
Secondary The blood routine and c-reactive protein of 216 participants will be assessed. Combined detection of c-reactive protein and white blood cell, if the two indicators return to normal after treatment, the child recovers. The maximum time for administration according to the protocol is 10 days, and the drug can be stopped at any time during clinical cure. If it is not good to change on the 6th day of treatment, use other measures.
Secondary Complete fever time Judging criteria: body temperature (underarm temperature) <37.3 ° C, and maintained for 24h and above. Measurement method: measured every 8h. The maximum time for administration according to the protocol is 10 days, and the drug can be stopped at any time during clinical cure. If it is not good to change on the 6th day of treatment, use other measures.
See also
  Status Clinical Trial Phase
Recruiting NCT05722938 - Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) Phase 3
Terminated NCT04972318 - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia N/A
Recruiting NCT06065618 - Characteristics of Hospitalized Patients With Community-acquired Pneumonia
Not yet recruiting NCT04166110 - Antibiotic Therapy In Respiratory Tract Infections N/A
Completed NCT02380352 - Short-course Antimicrobial Therapy for Paediatric Respiratory Infections Phase 4
Completed NCT01671280 - Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan) N/A
Completed NCT02555852 - Proton Pump Inhibitors and Risk of Community-acquired Pneumonia N/A
Recruiting NCT00752947 - Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors Phase 4
Completed NCT00140023 - Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia Phase 3
Recruiting NCT04089787 - Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia Phase 4
Completed NCT05356494 - Postural Drainage and PEP Technique in Community Acquired Pneumonia N/A
Completed NCT05133752 - Oral Nemonoxacin in Treating Elderly Patients With CAP Phase 4
Not yet recruiting NCT06291012 - Stopping Pneumonia Antibiotherapy Regimen Early Phase 4
Recruiting NCT05002192 - A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
Completed NCT03452826 - Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia N/A
Terminated NCT04071041 - Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia. Phase 3
Completed NCT03474991 - KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP Phase 3
Withdrawn NCT01662258 - Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP N/A
Completed NCT01723644 - Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia N/A
Completed NCT01683487 - Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia. Phase 4